Fda accepts dupixent® (dupilumab) for priority review in patients aged 12 years and older with eosinophilic esophagitis

If approved, dupixent would be the first medicine available in the u.s. indicated to treat eosinophilic esophagitis there are approximately 160,000 patients in the u.s. living with eosinophilic esophagitis who are currently treated, of whom approximately 48,000 have failed multiple treatments tarrytown, n.y. and paris , april 4, 2022  /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced the u.s. food and drug administration (fda) has accepted for priority review the supplemental biologics license application (sbla) for dupixent® (dupilumab) 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis (eoe), a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow.
REGN Ratings Summary
REGN Quant Ranking